Zeo ScientifiX Inc. · OTC:ZEOX
Zeo ScientifiX — Organicell Regenerative Medicine — Investor Presentation (October 2022)
17 slides from Zeo ScientifiX's investor presentation, Oct 12, 2022
Slide 1: Investor Presentation
At J oo*", ™ = Organicell << Investor Presentation > = = = > eS * @ October 10, 2022 = &> D @ @°o %e @ Private And Confidential. © 2022 Organicell Regenerative Medicine, Inc. All rights reserve
Slide 2: Forward Looking Statement
Forward Looking Statement Organiéell This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology including “anticipates,” “believes,” “can," “continue,” “could,” “estimates,” “expects,” “int
Slide 3: Organicell Snapshot
Organice!! Snapshot Organicell Regenerative Medicine, Inc. (OCEL) Organicell is a publicly-traded (OTCQB), clinical stage biopharmaceutical company that is committed to the research, development, and manufacture of new technologies in biologic medicine and therapeutics. “ Company was recapitalized a
Slide 4: Key Investment Considerations
Key Investment Considerations v v 4&8 & & & A & Underknown biotech company with diversified clinical trials Unique product offering ready to disrupt an enormous untapped market New management team with relevant domain expertise Current Accessible Capital $10MM Large addressable market Five (5) Inves
Slide 5: Business Overview
Business Overview Organiéell” Organicell is a clinical research company. Our mission is to be the first company to prove the efficacy of extracellular vesicles in clinical trials for several conditions. The Company generates revenue by extracting and delivering potent formulas of EVs for topical app
Slide 6: Understanding Organicell
Understanding Organicel! Organiéell Organicell Regenerative Medicine, Inc. (OCEL) is comprised of two arms: Clinical Research and Commercial. Organicell is focused on the characterization and utility of extracellular vesicles (also Known as Exosomes.) Clinical Research Commercial Organicell is activ
Slide 7: Product Overview
Product Overview Zofin™ is an acellular non HCT-P biologic derived from full term human amniotic fluid and is manufactured to retain the naturally occurring nanoparticles without the addition or combination of any other substance or diluent. This proprietary therapeutic contains over 300 soluble pro
Slide 8: Research Facility
Research Facility Private And Confidential. © 2022 Organicell Regenerative Medicine, 1c. All rights reserved. Organicell” Organicell Research & Manufacturing Facilities are located at the Nova South Eastern University Center for Collaborative Research. The company also maintains a commercial product
Slide 9: Research Data
Research Data Organiéelr What Makes Organicell Special? Supercharged Anti-Inflammatory Patent pending process enable the company to concentrate up to 600 billion EVs per milliliter, which contain over 300 cytokines, chemokines and growth factors. Clinical Data, elND's, IND’s 18 Emergency Investigati
Slide 10: Extracellular Vesicles
Extracellular Vesicles “> Extracellular vesicles (EVs) are a category of cell-derived membranous structures comprising of exosomes and microvesicles which originate from the endosomal system and plasma membrane. EVs are present in biological fluids and are instrumental in multiple physiological and
Slide 11: Exosome Basics
Exosome Basics *» Exosomes are a class of cell-derived extracellular vesicles of endosomal origin which are released by nearly all cell types and are present in all body fluids. “* Exosomes payload are very cell-specific, loaded with MicroRNAs (MiRs) and other bioactive contents. Private And Confide
Slide 12: Clinical Testing
Clinical Testing Zofin™ \nhibited T-cell Proliferation Clinical Model T-Cells are one of the important white blood cells Baseline of the immune system and play a central role in the adaptive immune response. In COVID long haulers and COPD cases, there are nod extended periods of inflammation when T-
Slide 13: Animal Testing
Animal Testing Measured testing results on rats after damaging their lungs and treating them with Organicell’s exosomes. mean linear intrcept (uM) o 8 8 a BB %, 4% en Yay ZS Normal Range % Inflammation Damage { om] After Exosome Treatment | | Muscularized Vessels (%) o & 8 a 8 Ph 4 4% ‘a ZN % Graphs
Slide 14: Clinical Testing
Clinical Testing Chest X-rays imaging and summary of key bio-markers on how Organicell’s Exosomes work on Covid patients AP View Lateral View Baseline Day 8 Day 30 Representative CXR images of patient at baseline, day 8, and day 30. Private And Confidential. © 2022 Organicell Regenerative Medicine,
Slide 15: Intellectual Property - Patent Update
Intellectual Property - Patent Update PPX FACTOR ><" Patent Pending Provisional Patent Patent Pendin Patent was filed on October 2021. Provisional protection filed Provisional filed on October 2022. Awaiting final comments on claims on October 2022. based on formula and process to and final approval
Slide 16: Organicell Team
Organicell Team Organicell Organicell’s world-class management team combines a proven track record in big business with science and regulatory expertise. Matt Sinnreich Ryan Likes Dr. Maria Mitrani Dr. George Shapiro lan T. Bothwell Dr. Mark Sinnreich Chief Executive Officer Chief Operating Officer
Slide 17: Comparable Investments
Comparable Investments MiMedx Group Inc. U.S. Nasdaq Vericel Corp. U.S: Nasdaq Organiéell” ® Market Open *2.9700 PES 0.07 2.41% * Oct 7, 2022, 11:17 AM EDT Real Time Quote About MiMedx Group Inc. MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and mar
Organicell Regenerative Medicine — Investor Presentation (October 2022) on 6ix